Dear colleagues, dear friends,

Clinical research is becoming increasingly complex with more constraints for investigators, stricter regulations, and exponentially growing costs for sponsors. In this context, it is essential to preserve and strengthen our academic research potential, particularly through cooperative oncology groups. In the face of this growing complexity, GORTEC is organizing itself by optimizing its partnership research and its internal processes. A key element for the group's sustainability is our ability to create new collaboration opportunities with industrial partners and to diversify our portfolio, which we are actively doing, among other things, by relying on the newly created Early Assets Board. The second ongoing project is to optimize the implementation of each study, ensuring a perfect match between needs and resources, reducing costs, and especially simplifying everything that can be simplified in the protocol, CRF, monitoring, etc. Supported by our strong and motivated operational team, all of this is currently being implemented through a pilot experience conducted for the upcoming study involving patients in the first-line relapse/metastatic setting (Tatiana study).

Driven by the strong involvement of our investigators and the efficiency of our operational team, GORTEC is more determined than ever to meet the growing challenges posed by clinical research!